Biotechnology Sanctions Compliance In Russia.

1. Introduction

Biotechnology sanctions compliance in Russia concerns the legal rules governing the development, manufacture, import, export, financing, distribution and international transfer of biotechnology products, materials, equipment, technologies and scientific knowledge when sanctions or export restrictions apply.

Biotechnology is particularly sensitive because certain products have both civilian and military applications. For example:

Genetic engineering and gene-editing technologies.

Recombinant proteins and biological materials.

Vaccines and pharmaceutical products.

Laboratory equipment and diagnostic instruments.

Genomic sequencing technologies.

Cell cultures and microorganisms.

Biological research software.

Advanced fermentation and biomanufacturing equipment.

Pathogen detection and biological testing systems.

A biotechnology company may therefore face several overlapping legal obligations: Russian domestic law, foreign export-control legislation, international sanctions, contractual restrictions and biological safety requirements.

An important distinction: Russia's domestic counter-sanctions legislation and sanctions imposed by foreign jurisdictions are different legal regimes. A transaction may be lawful under Russian law but prohibited under EU, US or UK law because of the nationality of the exporter, the origin of the technology, the involvement of a listed person or the destination of the goods.

2. Legal framework governing biotechnology sanctions in Russia

Russia's biotechnology sanctions compliance framework operates through several legal instruments.

A. Federal Law No. 183-FZ of 18 July 1999 — On Export Control

This is one of the principal Russian laws governing the export of controlled goods, technologies, information and services.

Its relevance to biotechnology includes:

Export of microorganisms and biological materials.

Transfer of controlled genetic-engineering technologies.

International supply of specialised laboratory equipment.

Transfer of scientific and technical information.

Transactions involving biological agents that could have military applications.

Export licensing and compliance procedures.

The legislation establishes the basis for controlling foreign economic activities involving goods and technologies that may contribute to weapons of mass destruction or other controlled military applications.

B. Government Resolution No. 634 of 29 August 2001

This resolution establishes controls over foreign economic activities involving microorganisms, toxins, equipment and technologies.

It is particularly important for biotechnology companies involved in:

Microbial research.

Biological production systems.

Toxin-related scientific materials.

Advanced laboratory technologies.

International transfers of controlled biological equipment.

The controls are relevant to commercial enterprises, research institutions and individuals conducting covered foreign economic activities.

C. Federal Law No. 281-FZ of 30 December 2006 — On Special Economic Measures

This legislation provides a framework for Russian special economic measures and restrictive measures.

Its significance for biotechnology businesses includes the potential effect of restrictive measures on international transactions, commercial relationships, financial operations and dealings with specified foreign persons or entities.

D. Criminal Code of the Russian Federation

Two provisions are especially important:

Article 189: Illegal export or transfer of goods or technologies subject to export control.

Article 355: Criminal liability relating to the development, production, stockpiling, acquisition or sale of weapons of mass destruction.

Article 189 is particularly relevant when biotechnology equipment, biological materials or technical information are transferred unlawfully to foreign recipients.

E. Code of Administrative Offences

Article 14.20 addresses violations of export-control legislation.

It covers, among other things, transactions requiring special authorisation that are conducted without the necessary licence, violations of licence conditions and the use of unlawfully obtained licences.

It also addresses failures in export-control recordkeeping.

Consultant Plus+2

3. Foreign sanctions affecting Russian biotechnology

Russian biotechnology businesses may be affected by sanctions imposed by the European Union, United States and United Kingdom.

These regimes must be examined independently because their territorial reach, prohibited activities and licensing exceptions differ.

A. European Union sanctions

The principal instrument is Council Regulation (EU) No 833/2014.

Its restrictions include:

Export prohibitions on dual-use goods and technologies.

Restrictions on specified advanced technologies.

Restrictions concerning military and industrial end-users.

Restrictions on technical assistance and brokering.

Restrictions on specified financial and commercial transactions.

Biotechnology equipment may become controlled when its technical specifications or intended applications fall within the relevant controlled-goods lists.

A critical distinction exists between ordinary medical products and dual-use biological technologies.

For example, an ordinary diagnostic instrument may be treated differently from specialised equipment or technology capable of supporting controlled biological research.

Medical and pharmaceutical exemptions

Article 2(3) of Regulation 833/2014 contains provisions concerning certain humanitarian, medical and pharmaceutical activities.

However, the exemption is conditional. It does not provide a general permission to export every biotechnology product to Russia.

The amended framework also excludes specified products listed in Annex XL from the relevant medical and pharmaceutical exemption.

The exporter must assess the classification, recipient, end-use and applicable authorisation requirements.

EUR-Lex+2

 

B. United States sanctions

US sanctions compliance involves two principal legal frameworks:

Office of Foreign Assets Control (OFAC) sanctions.

Export Administration Regulations (EAR), administered by the Bureau of Industry and Security (BIS).

OFAC restrictions may prohibit dealings involving designated Russian persons, entities and organisations.

The EAR may control the export, re-export or transfer of US-origin goods, software and technology to Russia.

Biotechnology businesses should particularly examine:

Laboratory equipment originating in the United States.

Genomic sequencing systems.

Advanced scientific instruments.

Specialised biological manufacturing equipment.

Controlled software and technical information.

Transactions involving restricted Russian research institutions.

The existence of a medical or humanitarian purpose does not automatically remove all sanctions or export-control restrictions.

C. United Kingdom sanctions

The principal instrument is the Russia (Sanctions) (EU Exit) Regulations 2019.

An important development occurred in 2026: the UK added engineering biology ancillary goods to its sanctions framework.

The relevant Schedule 3C provisions include:

Cell cultures, subject to stated exclusions.

Enzymes and prepared enzymes.

Prepared culture media.

Diagnostic and laboratory reagents.

Microarray scanners and printers.

Gene-editing tools, including CRISPR-Cas9 and TALENs.

Chemostats and microfluidic bioreactors.

Roller bottles used for cell culture.

This development makes UK engineering-biology restrictions particularly relevant to international biotechnology supply chains.

The UK also provides specific licensing considerations for certain humanitarian, health-emergency and other permitted activities. A licence must be obtained before undertaking an otherwise prohibited activity.

Legislation.gov.uk+1

 

4. Biotechnology activities requiring sanctions screening

Biotechnology activityPrincipal compliance concern
Genetic engineeringDual-use export controls
CRISPR technologyControlled technology and equipment
Vaccine developmentMedical exemptions and biological controls
Recombinant proteinsProduct classification and end-use
Genomic sequencingTechnology and software restrictions
Cell cultureBiological material restrictions
Laboratory equipmentExport licensing
Clinical trialsFinancial, institutional and research restrictions
Biotechnology softwareTechnology-transfer controls
Biological samplesExport, biosafety and end-user restrictions

The legal classification depends on the actual product, its technical specifications, destination, intended use and applicable jurisdiction. Merely describing a product as a medical or research product does not determine its legal status.

5. Corporate sanctions compliance obligations

Russian biotechnology companies conducting international transactions should establish a structured compliance programme.

A. Customer and beneficial ownership screening

Companies should identify:

The immediate purchaser.

The ultimate beneficial owner.

The final recipient.

The research institution receiving the product.

Intermediaries and distributors.

Persons exercising control over the recipient.

Screening should include relevant sanctions lists maintained by the jurisdictions connected with the transaction.

B. Product classification

Every biotechnology product should undergo technical classification.

For example, a company exporting laboratory equipment should establish whether the equipment is:

Ordinary commercial equipment.

Specialised scientific equipment.

Dual-use equipment.

Controlled biological equipment.

Subject to a specific sanctions prohibition.

C. End-user verification

The exporter should obtain reliable information concerning the recipient and the final use.

A distributor's declaration alone may not be sufficient where there are warning signs of diversion.

D. Export licensing

Where an authorisation is required, the company must obtain it before shipment or transfer.

The same principle applies to controlled technical assistance, software access and technology transfers.

E. Financial sanctions screening

Biotechnology companies should examine:

Banks involved in payments.

Insurance providers.

Investors and shareholders.

Financing arrangements.

Payment intermediaries.

Sanctioned counterparties.

F. Documentation and audit trails

Companies should retain:

Product classification records.

Export licences.

Customer due-diligence documents.

End-user certificates.

Contracts and invoices.

Shipping records.

Sanctions screening results.

Internal compliance approvals.

These records help demonstrate that the organisation exercised appropriate compliance controls.

6. Liability for biotechnology sanctions violations

Sanctions violations may result in administrative, criminal, commercial and regulatory consequences.

A. Administrative liability — Article 14.20

Article 14.20 of the Russian Code of Administrative Offences provides liability for violations of export-control requirements.

Potential violations include:

Conducting controlled exports without mandatory authorisation.

Providing inaccurate export documentation.

Breaching licence conditions.

Failing to maintain prescribed transaction records.

The provision allows administrative fines linked to the value of the goods, information, services or intellectual-property results involved. Confiscation may also be imposed.

B. Criminal liability — Article 189

Article 189 of the Russian Criminal Code criminalises unlawful exports or transfers to foreign persons of goods and technologies subject to export control.

The provision is especially significant for biotechnology because it expressly addresses controlled goods and technologies that may be used in developing weapons of mass destruction.

The penalties depend on the circumstances:

OffencePotential imprisonment
Basic offence under Article 189(1)3–7 years
Aggravated offence under Article 189(2)5–10 years
Organised-group offence under Article 189(3)7–12 years

The prosecution must establish the relevant statutory elements, including the person's knowledge of the applicable export-control restrictions.

Article 189 should not be interpreted as criminalising every breach of a foreign sanctions regime. Its application depends on Russian criminal law and the specific conduct involved.

Consultant Plus+1

 

7. Important case laws and judicial authorities

There is an important limitation in this area: publicly identifiable judicial precedents specifically concerning biotechnology sanctions compliance in Russia are limited. Consequently, the following decisions are relevant comparative and interpretative authorities rather than a collection of direct Russian biotechnology judgments.

Case 1. PJSC Rosneft Oil Company v Her Majesty's Treasury and Others (2017)

Important sanctions precedent

Court: Court of Justice of the European Union.

Case number: C-72/15.

Decision date: 28 March 2017.

Citation: ECLI:EU:C:2017:236.

Background

Rosneft challenged restrictive measures adopted by the European Union following the crisis involving Ukraine.

The dispute concerned restrictions on financial transactions, access to capital markets and exports of sensitive technologies to Russia.

Legal issues

The Court examined:

The legality of restrictive measures.

The interpretation of sanctions regulations.

Legal certainty.

Judicial review of restrictive measures.

The rights of affected companies.

Judgment

The Court upheld the validity of the relevant restrictive measures and confirmed its jurisdiction to examine the validity of certain EU restrictive measures through preliminary references.

Relevance to biotechnology

The judgment provides an important legal foundation for understanding how EU restrictions can affect Russian companies operating in technologically sensitive industries.

A biotechnology company cannot assume that its commercial operations are exempt merely because its activities are civilian.

EUR-Lex+1

Case 2. Russia — Measures Concerning Traffic in Transit (2019)

Court: World Trade Organization Dispute Settlement Body.

Case number: WT/DS512.

Complainant: Ukraine.

Respondent: Russian Federation.

Report adopted: 26 April 2019.

Background

Ukraine challenged Russian restrictions affecting traffic in transit through Russian territory.

Russia relied on the national-security exception under Article XXI(b) of the General Agreement on Tariffs and Trade.

Legal issues

The dispute concerned:

National-security exceptions.

International trade restrictions.

The interpretation of security interests.

The limits of WTO review.

Decision

The WTO Panel examined the requirements for invoking the national-security exception and recognised that the exception was not entirely beyond judicial examination.

Relevance to biotechnology

The decision is relevant to international biotechnology trade because restrictions on the movement of biological materials, laboratory equipment and research products may create disputes involving national security and international trade obligations.

It does not establish a general exemption for biotechnology exports.

DS512+1

 

Case 3. Euro Asia Cargo Private Ltd v Council of the European Union (2026)

Recent dual-use sanctions judgment

Court: General Court of the European Union.

Case number: T-232/24.

Decision date: 14 January 2026.

Citation: ECLI:EU:T:2026:2.

Background

The case concerned restrictive measures associated with Russia and the inclusion and continued listing of an entity in connection with dual-use goods and technology.

Legal issues

The Court considered:

The right to be heard.

The obligation to provide adequate reasons.

Errors of assessment.

The legality of restrictive listings.

Freedom to conduct a business.

Relevance to biotechnology

The judgment is particularly useful when examining companies involved in international distribution of biotechnology equipment and other dual-use products.

It illustrates that sanctions enforcement must operate within applicable procedural and judicial-review requirements.

Companies affected by restrictive listings may have grounds to challenge measures where the legal requirements for listing have not been satisfied.

However, the case is not a direct judgment concerning biological materials or genetic engineering.

EUR-Lex

 

8. International biological security and sanctions compliance

Biotechnology sanctions compliance also intersects with international biological security obligations.

An important instrument is the Biological Weapons Convention (BWC).

The Convention prohibits the development, production, stockpiling, acquisition and retention of biological agents and toxins of types and quantities that have no justification for prophylactic, protective or other peaceful purposes.

For Russian biotechnology businesses, this creates an important distinction between:

Legitimate biological research.

Commercial pharmaceutical manufacturing.

Vaccine development.

Public-health research.

Prohibited biological weapons activities.

Russia's export-control framework also includes Government Resolution No. 634 of 2001, which specifically addresses controlled microorganisms, toxins, equipment and technologies.

The UN documentation concerning the BWC identifies these Russian regulatory controls and their relationship with domestic criminal liability.

UN Official Document System

 

9. Practical examples of sanctions compliance

Consider the following hypothetical situations.

Example 1: Export of genetic-engineering equipment

A Russian biotechnology company purchases advanced gene-editing equipment from a European supplier.

Before completing the transaction, the parties must examine the equipment's technical classification, the applicable export restrictions, the ultimate end-user and any necessary authorisation.

Legal issue: Whether the equipment is subject to dual-use or engineering-biology controls.

Example 2: Vaccine research collaboration

A Russian pharmaceutical company enters into a vaccine-development agreement with a foreign research institution.

The parties must assess whether the transfer of biological samples, technology, research data, equipment or technical assistance is restricted.

Legal issue: Whether the relevant medical or pharmaceutical exemptions apply and whether separate biological-material restrictions exist.

Example 3: Payment through an intermediary

A Russian biotechnology company attempts to pay a foreign laboratory through an intermediary bank.

The transaction requires screening of the participating financial institutions, beneficial owners and relevant counterparties.

Legal issue: Whether the payment would constitute a prohibited transaction involving a designated person or restricted financial institution.

Example 4: Transfer of cell cultures

A research institution exports cell cultures to a foreign biotechnology laboratory.

The organisation must determine whether the cultures are controlled biological materials or fall within applicable sanctions restrictions.

Legal issue: Whether export authorisation, biological safety requirements or additional sanctions screening is necessary.

10. Compliance strategies for Russian biotechnology companies

A legally effective compliance programme should include the following measures:

Compliance measureLegal objective
Sanctions screeningIdentify restricted counterparties
Export classificationDetermine controlled-product status
End-user verificationPrevent prohibited diversion
Licence managementEnsure lawful transfers
Banking due diligenceAvoid prohibited financial transactions
Contractual safeguardsAllocate compliance responsibilities
Employee trainingReduce internal violations
RecordkeepingEstablish documentary evidence
Internal investigationsIdentify and address violations
Independent auditsEvaluate compliance effectiveness

Companies should also adopt contractual clauses addressing sanctions changes, suspension of prohibited transactions, disclosure obligations and termination rights.

Importantly, contractual clauses cannot make an otherwise prohibited transaction lawful.

11. Major legal challenges

Several unresolved challenges affect biotechnology sanctions compliance in Russia.

1. Dual-use classification uncertainty

A laboratory instrument may support both civilian medical research and activities subject to military export controls.

2. Medical exemption uncertainty

The distinction between ordinary medical research and restricted dual-use technology may be difficult to establish.

3. Cross-border research restrictions

International scientific collaboration can involve the transfer of technical information, software and biological materials.

4. Third-country intermediaries

Transactions routed through third countries may still be subject to sanctions and anti-circumvention restrictions.

5. Conflicting legal obligations

A company may face different obligations under Russian domestic legislation and the sanctions legislation of the country from which it obtains equipment or technology.

6. Changing sanctions lists

Frequent amendments to controlled-goods lists require continuous compliance monitoring.

7. Access to scientific technology

Restrictions may affect the availability of advanced sequencing instruments, specialised laboratory equipment and manufacturing technologies.

12. Conclusion

Biotechnology sanctions compliance in Russia is a complex area involving export controls, international sanctions, biological security, financial restrictions and corporate accountability.

Federal Law No. 183-FZ, Government Resolution No. 634 of 2001, the Russian Criminal Code and the Code of Administrative Offences provide important domestic legal foundations.

Meanwhile, EU Regulation 833/2014, US sanctions and export-control requirements, and the UK Russia (Sanctions) (EU Exit) Regulations 2019 can impose additional obligations on international biotechnology transactions.

The principal legal lesson is that biotechnology companies must examine not only the nature of their products but also their origin, destination, end-user, ownership structure, intended application and associated financial transactions.

A functioning sanctions compliance system is therefore essential to protecting legitimate biotechnology research, pharmaceutical development, international commercial relationships and biological security.

13. Important legislation and reference materials

Legal instrumentPrincipal relevance
Russian Federal Law No. 183-FZ (1999)Export control
Government Resolution No. 634 (2001)Microorganisms, toxins and related technology
Federal Law No. 281-FZ (2006)Special economic measures
Russian Criminal Code, Article 189Illegal controlled exports
Russian Criminal Code, Article 355Weapons of mass destruction
Russian Administrative Code, Article 14.20Export-control violations
EU Regulation No. 833/2014Russia-related restrictive measures
US Export Administration RegulationsExport and re-export controls
UK Regulations 2019/855Russia-related sanctions
Biological Weapons ConventionInternational biological security

Primary research sources

Russian Criminal Code — Article 189.

Russian Administrative Code — Article 14.20.

EU Regulation 833/2014 — consolidated legislation.

UK Government — Russia sanctions licensing guidance.

Rosneft judgment — Case C-72/15.

Euro Asia Cargo — Case T-232/24.

WTO — Russia Traffic in Transit, DS512.

Academic note: The judicial authorities discussed above should not be presented as direct Russian biotechnology sanctions convictions. They are relevant export-control, international-trade and sanctions precedents that help explain the applicable legal principles. Russian domestic enforcement must be researched separately through individual court decisions and prosecutorial records.

LawGratis provides pro bono legal aid and resources to empower communities. Join us in making justice reachable for everyone! Follow our community on Instagram, YouTube, Facebook, and LinkedIn.

LEAVE A COMMENT